Lilly's Q4 2025 revenue rose 43%; 2026 guidance set at $80B-$83B

Eli Lilly reported fourth-quarter 2025 revenue of $19.3 billion, up 43% from a year earlier, driven by volume growth for Mounjaro and Zepbound. Non-GAAP earnings per share were $7.54, up 42%. The company guided 2026 revenue to $80 billion to $83 billion and non-GAAP EPS to $33.50 to $35.00, which set the bar that later raises were measured against.

• Q4 2025 revenue $19,292M, up 43%
• Reported EPS $7.39 (up 51%); non-GAAP EPS $7.54 (up 42%)
• 2026 revenue guidance $80B-$83B
• 2026 non-GAAP EPS guidance $33.50-$35.00

SEC filing 8-K · accession 0000059478-26-000008 · sec.gov ↗